---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-025238"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2025-02-24T23:59:59+00:00"
generated_at: "2026-05-26T06:08:51.109550+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Tivic Health names Michael Handley COO and President of Tivic Biopharma following Statera license

## Summary
- Handley appointed COO and President of new Tivic Biopharma division, effective Feb 18, 2025.
- Compensation: $300k base salary, up to 35% bonus, 600k RSUs vesting over 4 years.
- Handley previously CEO of Statera Biopharma; helped commercialize 17 drugs/devices worth ~$7B in sales.
- Role includes advancing late-stage Entolimod (TLR5 agonist) for radiation protection and immune indications.
- Appointment follows Feb 11 exclusive license of Entolimod from Statera, previously disclosed.

## SEC filing metadata
- accession: 0000950170-25-025238
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2025-02-24T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000095017025025238/0000950170-25-025238-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000095017025025238/tivc-20250218.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-025238
- JSON: https://secwatch.observer/filing/0000950170-25-025238.json
- Plain text: https://secwatch.observer/filing/0000950170-25-025238.txt

## Key facts
- Executive change
  Michael Handley was appointed as Chief Operating Officer and President of Tivic Biopharma division at Valion Bio, Inc..
  - Action: appointed
  - Role: Chief Operating Officer and President of Tivic Biopharma division
  source text: On February 18, 2025, Michael Handley was appointed as Chief Operating Officer of Tivic Health Systems, Inc., a Delaware corporation (the “Company”), and President of the Company’s Tivic Biopharma division.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787740/000095017025025238/0000950170-25-025238-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.